Repare Therapeutics (RPTX)
Market Price (1/28/2026): $2.65 | Market Cap: $113.9 MilSector: Health Care | Industry: Biotechnology
Repare Therapeutics (RPTX)
Market Price (1/28/2026): $2.65Market Cap: $113.9 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -99% | Trading close to highsDist 52W High is 0.0% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -79 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -667% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -97% | Weak multi-year price returns2Y Excs Rtn is -101%, 3Y Excs Rtn is -153% | Stock price has recently run up significantly12M Rtn12 month market price return is 130% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -82%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -39% | |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 104% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -591%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -591% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -68% | ||
| Key risksRPTX key risks include [1] the potential for disappointing results from its pivotal POLAR and LIONS trials, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -99% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -97% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Trading close to highsDist 52W High is 0.0% |
| Weak multi-year price returns2Y Excs Rtn is -101%, 3Y Excs Rtn is -153% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -79 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -667% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 130% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -82%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -39% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 104% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -591%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -591% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -68% |
| Key risksRPTX key risks include [1] the potential for disappointing results from its pivotal POLAR and LIONS trials, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Repare Therapeutics (RPTX) stock has gained about 50% since 9/30/2025 because of the following key factors:
1. Acquisition Agreement by XenoTherapeutics. Repare Therapeutics entered a definitive arrangement to be acquired by XenoTherapeutics, with the transaction expected to close in Q1 2026. The deal includes an estimated cash payment of $1.82 per share plus one non-transferable Contingent Value Right (CVR) per share, which entitles holders to specified percentages of future partnership and disposition proceeds. This acquisition provides a clear valuation and return to shareholders, likely driving the stock price up towards the implied acquisition value.
2. Strong Q3 2025 Financial Performance. On November 14, 2025, Repare Therapeutics reported its Q3 2025 financial results, significantly surpassing analyst expectations. The company announced earnings per share (EPS) of $0.08, considerably beating the consensus estimate of -$0.35. Additionally, quarterly revenue of $11.62 million exceeded the consensus estimate of $7.50 million, indicating strong operational performance.
Show more
1. Acquisition Agreement by XenoTherapeutics. Repare Therapeutics entered a definitive arrangement to be acquired by XenoTherapeutics, with the transaction expected to close in Q1 2026. The deal includes an estimated cash payment of $1.82 per share plus one non-transferable Contingent Value Right (CVR) per share, which entitles holders to specified percentages of future partnership and disposition proceeds. This acquisition provides a clear valuation and return to shareholders, likely driving the stock price up towards the implied acquisition value.
2. Strong Q3 2025 Financial Performance. On November 14, 2025, Repare Therapeutics reported its Q3 2025 financial results, significantly surpassing analyst expectations. The company announced earnings per share (EPS) of $0.08, considerably beating the consensus estimate of -$0.35. Additionally, quarterly revenue of $11.62 million exceeded the consensus estimate of $7.50 million, indicating strong operational performance.
Show more
Stock Movement Drivers
Fundamental Drivers
The 50.6% change in RPTX stock from 9/30/2025 to 1/27/2026 was primarily driven by a 4648.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 9302025 | 1272026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.76 | 2.65 | 50.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 12 | 4648.0% |
| P/S Multiple | 302.2 | 9.6 | -96.8% |
| Shares Outstanding (Mil) | 43 | 43 | -0.1% |
| Cumulative Contribution | 50.6% |
Market Drivers
9/30/2025 to 1/27/2026| Return | Correlation | |
|---|---|---|
| RPTX | 50.6% | |
| Market (SPY) | 4.4% | -0.1% |
| Sector (XLV) | 11.7% | 6.6% |
Fundamental Drivers
The 90.6% change in RPTX stock from 6/30/2025 to 1/27/2026 was primarily driven by a 1006.2% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302025 | 1272026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.39 | 2.65 | 90.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 12 | 1006.2% |
| P/S Multiple | 55.2 | 9.6 | -82.6% |
| Shares Outstanding (Mil) | 43 | 43 | -0.9% |
| Cumulative Contribution | 90.6% |
Market Drivers
6/30/2025 to 1/27/2026| Return | Correlation | |
|---|---|---|
| RPTX | 90.6% | |
| Market (SPY) | 12.9% | 6.1% |
| Sector (XLV) | 15.9% | 17.8% |
Fundamental Drivers
The 102.3% change in RPTX stock from 12/31/2024 to 1/27/2026 was primarily driven by a 1047.4% change in the company's P/S Multiple.| (LTM values as of) | 12312024 | 1272026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.31 | 2.65 | 102.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 67 | 12 | -82.2% |
| P/S Multiple | 0.8 | 9.6 | 1047.4% |
| Shares Outstanding (Mil) | 42 | 43 | -1.2% |
| Cumulative Contribution | 102.3% |
Market Drivers
12/31/2024 to 1/27/2026| Return | Correlation | |
|---|---|---|
| RPTX | 102.3% | |
| Market (SPY) | 19.7% | 10.7% |
| Sector (XLV) | 14.5% | 17.0% |
Fundamental Drivers
The -82.0% change in RPTX stock from 12/31/2022 to 1/27/2026 was primarily driven by a -90.2% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 12312022 | 1272026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.71 | 2.65 | -82.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 121 | 12 | -90.2% |
| P/S Multiple | 5.1 | 9.6 | 87.3% |
| Shares Outstanding (Mil) | 42 | 43 | -2.4% |
| Cumulative Contribution | -82.0% |
Market Drivers
12/31/2022 to 1/27/2026| Return | Correlation | |
|---|---|---|
| RPTX | -82.0% | |
| Market (SPY) | 88.6% | 18.7% |
| Sector (XLV) | 19.8% | 16.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RPTX Return | -39% | -30% | -50% | -82% | 98% | 1% | -92% |
| Peers Return | 6% | -30% | 47% | 0% | 7% | 9% | 27% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 2% | 85% |
Monthly Win Rates [3] | |||||||
| RPTX Win Rate | 33% | 42% | 42% | 33% | 67% | 100% | |
| Peers Win Rate | 50% | 48% | 57% | 45% | 50% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| RPTX Max Drawdown | -43% | -60% | -78% | -83% | -31% | -3% | |
| Peers Max Drawdown | -27% | -54% | -32% | -24% | -37% | -3% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: IDYA, EXEL, ORIC, LLY, APRE.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/27/2026 (YTD)
How Low Can It Go
| Event | RPTX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -92.8% | -25.4% |
| % Gain to Breakeven | 1280.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -34.7% | -33.9% |
| % Gain to Breakeven | 53.1% | 51.3% |
| Time to Breakeven | 54 days | 148 days |
Compare to IDYA, EXEL, ORIC, LLY, APRE
In The Past
Repare Therapeutics's stock fell -92.8% during the 2022 Inflation Shock from a high on 1/7/2021. A -92.8% loss requires a 1280.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Repare Therapeutics (RPTX)
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
AI Analysis | Feedback
Moderna or BioNTech, but for discovering precision cancer medicines using a genetic screening platform.
A next-generation Blueprint Medicines or Loxo Oncology, specializing in finding cancer vulnerabilities through a unique approach called synthetic lethality.
AI Analysis | Feedback
```html- RP-3500 (camonsertib): An ATR inhibitor in clinical development for the treatment of solid tumors with specific genetic alterations such as ATM mutations.
- RP-6306: A PKMYT1 inhibitor being investigated for its potential to treat solid tumors with specific genetic alterations like CCNE1 amplification.
- Lunresertib (RP-9036): A Polθ inhibitor in partnership with Roche, currently in Phase 1 clinical trials for advanced solid tumors.
AI Analysis | Feedback
Repare Therapeutics (RPTX) is a clinical-stage precision oncology company focused on developing novel synthetic lethality medicines. As such, it sells primarily to other companies rather than individuals. Its revenue is primarily derived from collaboration and license agreements with larger pharmaceutical companies. The major customer companies of Repare Therapeutics are: * **F. Hoffmann-La Roche Ltd** (SIX: ROG, OTCQX: RHHBY) – Repare has a significant collaboration agreement with Roche (and its subsidiary Genentech) for the development and commercialization of ATR inhibitors. * **Bristol Myers Squibb Company** (NYSE: BMY) – Repare has a collaboration agreement with Bristol Myers Squibb for the discovery, development, and commercialization of precision oncology medicines.AI Analysis | Feedback
nullAI Analysis | Feedback
Steve Forte, President, Chief Executive Officer & Chief Financial Officer
Mr. Forte was appointed President, CEO, and CFO of Repare Therapeutics in April 2025, having previously served as Executive Vice President and CFO since October 2019. Prior to joining Repare, he served as Chief Financial Officer of Clementia Pharmaceuticals Inc., which was acquired by Ipsen S.A. for $1.3 billion. He also previously served as Chief Financial Officer of Thinking Capital Financial Corporation, a Canadian financial technology firm, where he ultimately led the firm through a sale to Purpose Investments. Mr. Forte held various financial leadership roles at Aptalis Pharma Inc. and CST Canada Co. from 2005 to 2015.
Michael Zinda, Ph.D., Executive Vice President & Chief Scientific Officer
Dr. Zinda serves as the Executive Vice President and Chief Scientific Officer at Repare Therapeutics. His prior experience includes serving as executive director of Cancer Biosciences at AstraZeneca.
Maria Koehler, M.D., Ph.D., Executive Vice President & Chief Medical Officer
Dr. Koehler is the Executive Vice President and Chief Medical Officer at Repare Therapeutics. Her previous roles include serving as Chief Medical Officer of Bicycle Therapeutics and Vice President of Strategy for Pfizer Oncology.
Daniel Bélanger, Executive Vice President, Human Resources
Mr. Bélanger joined Repare Therapeutics as Executive Vice President, Human Resources in May 2023. He brings 25 years of global Human Resources experience within the life science industry, having previously served as Chief Human Resources Officer at another company and held progressive global leadership roles in Human Resources for 17 years at Aptalis Pharma, formerly Axcan Pharma.
Sandra Alves, Chief Accounting Officer
Ms. Alves has been promoted to Chief Accounting Officer at Repare Therapeutics. Prior to this role, she served as Vice President and Corporate Controller at the company.
AI Analysis | Feedback
The key risks to Repare Therapeutics (RPTX) are primarily associated with the inherent challenges of a clinical-stage biotechnology company, its financial sustainability, and broader market dynamics.
- Clinical Trial Outcomes and Regulatory Approval: As a clinical-stage oncology company, Repare Therapeutics' success hinges on the outcomes of its ongoing and future clinical trials. There is a significant risk that positive results observed in preclinical testing and earlier clinical trials may not be replicated in later-stage trials, or that the data generated may not be sufficient to demonstrate the efficacy and safety of a product candidate to regulatory authorities. Disappointing results from pivotal trials, such as POLAR and LIONS, could significantly impact the company's prospects. The uncertainties and timing associated with the regulatory approval process also pose a substantial risk.
- Need for Additional Funding: Repare Therapeutics requires substantial additional capital to finance its operations and advance its pipeline. While the company benefits from collaboration and licensing agreements, and potential milestone payments can provide non-dilutive funding, the sustainability and realization of these revenues are not guaranteed. A potential increase in research and development (R&D) and operational expenses could necessitate raising capital through equity markets sooner than anticipated, potentially leading to dilution for existing shareholders. The company recently undertook a significant workforce reduction of approximately 75% to extend its cash runway, indicating existing financial pressures.
- Competition and Macroeconomic Conditions: Repare Therapeutics operates in a highly competitive biopharmaceutical landscape, facing risks from changes in expected or existing competition. Furthermore, broader macroeconomic conditions, including fluctuations in inflation, uncertain credit and financial markets, and geopolitical events (such as conflicts in Ukraine and the Middle East), can adversely impact the company's business, its ability to conduct clinical trials, and its overall financial position.
AI Analysis | Feedback
nullAI Analysis | Feedback
Repare Therapeutics (symbol: RPTX) is a clinical-stage precision oncology company with several main product candidates in its pipeline.
For their product candidates, the addressable markets are identified as follows:
- Lunresertib (RP-6306): This is a PKMYT1 inhibitor. The global PKMYT1 inhibitors market was valued at USD 90.2 million in 2024 and is projected to grow to USD 1.1 billion by 2035, with a Compound Annual Growth Rate (CAGR) of 25.7% from 2025 to 2030.
- Camonsertib (RP-3500): This is an ATR inhibitor. The global ATR Kinase Inhibitor market size reached USD 1.24 billion in 2024 and is expected to grow to USD 5.13 billion by 2033, expanding at a CAGR of 17.8% from 2025 to 2033.
- RP-1664: This is a PLK4 inhibitor designed to target TRIM37-high solid tumors, including neuroblastoma and breast cancer. A specific addressable market size for "TRIM37-high solid tumors" or for PLK4 inhibitors in monetary terms could not be identified.
- RP-3467: This is a Polθ ATPase inhibitor associated with BRCA mutations and other genomic alterations, targeting molecularly selected advanced solid tumors such as ovarian, breast, metastatic castration-resistant prostate, and pancreatic adenocarcinoma. The global BRCA Mutations Treatment Market was valued at approximately USD 4.37 billion in 2023 and is projected to reach USD 4.88 billion in 2024. The global BRCA Mutation-Positive Ovarian Cancer Market was valued at USD 1874.78 million in 2024 and is expected to increase to USD 3607.17 million by 2031, growing at a CAGR of 9.8%. North America accounts for over 38% of this global market. Additionally, the global market for Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) Genes, which RP-3467 targets, was USD 5.62 billion in 2022 and is expected to reach USD 11.28 billion by 2030, with a CAGR of 9.10% during the forecast period from 2023 to 2030.
AI Analysis | Feedback
Repare Therapeutics (RPTX) is a clinical-stage precision oncology company, and its future revenue growth over the next 2-3 years is expected to be primarily driven by its strategic collaborations and the advancement of its pipeline programs. Here are 3-5 expected drivers of future revenue growth:- Milestone Payments and Royalties from Licensing Agreements: Repare Therapeutics generates revenue through collaboration and license agreements with larger pharmaceutical partners, receiving upfront payments, milestone payments tied to research, development, and regulatory progress, and potential future royalties on product sales. A significant driver will be the exclusive worldwide licensing agreement with Debiopharm for lunresertib (a first-in-class PKMYT1 inhibitor), signed in July 2025. This agreement includes a $10 million upfront payment and eligibility for up to $257 million in potential clinical, regulatory, commercial, and sales milestones, as well as single-digit royalties on global net sales.
- Advancement and Potential Commercialization of Clinical Pipeline (RP-1664 and RP-3467): The company has reprioritized its clinical portfolio to focus on advancing three ongoing Phase 1 clinical trials: RP-1664 (LIONS trial, a PLK4 inhibitor) and RP-3467 (POLAR trial, a Polθ ATPase inhibitor), and lunresertib in combination with Debiopharm's WEE1 inhibitor, Debio 0123. Initial data readouts for the LIONS and POLAR trials are expected in the fourth quarter of 2025. Positive clinical trial results for these candidates could trigger further milestone payments from existing or new partnerships and pave the way for future commercialization, thereby contributing to revenue growth.
- New Strategic Partnerships and Out-licensing Opportunities: Repare is actively exploring strategic alternatives and partnerships across its portfolio to enhance long-term shareholder value. This includes seeking partnering opportunities for programs like the lunresertib and camonsertib combination. Any new collaboration agreements for its innovative pipeline assets, particularly those utilizing its proprietary SNIPRx® platform, could lead to additional upfront payments and milestone revenues.
AI Analysis | Feedback
Share Issuance
- Repare Therapeutics had significant capital stock issuances of $247.84 million in 2020 and $95.56 million in 2021, likely associated with its initial public offering in 2020.
- Smaller capital stock issuances were reported at $0.88 million in 2022, $0.84 million in 2023, and $0.54 million in 2025.
- The number of shares outstanding increased by 0.92% year-over-year as of October 28, 2025.
Inbound Investments
- The company entered into an exclusive worldwide licensing agreement with Debiopharm for lunresertib, receiving a $10 million upfront payment and up to $257 million in potential milestone payments and royalties.
- Repare Therapeutics out-licensed discovery platforms to DCx Biotherapeutics, which included a $1 million upfront payment, $3 million in near-term payments, 9.99% equity, anti-dilution rights, and future milestones.
- A collaboration with Bristol Myers Squibb was established (mentioned in 2020 filings) to leverage Repare's SNIPRx platform for the discovery and development of oncology medicines.
Capital Expenditures
- Capital expenditures were reported as $0 in the last 12 months (prior to late 2024/early 2025), indicating minimal spending on long-term assets during this period.
- The company's primary focus for capital allocation is on advancing its clinical-stage precision oncology pipeline, which includes candidates like lunresertib, camonsertib, RP-1664, and RP-3467.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| How Low Can Repare Therapeutics Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 23.43 |
| Mkt Cap | 2.1 |
| Rev LTM | 113 |
| Op Inc LTM | -47 |
| FCF LTM | -60 |
| FCF 3Y Avg | -97 |
| CFO LTM | -42 |
| CFO 3Y Avg | -53 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 23.4% |
| Rev Chg 3Y Avg | 17.6% |
| Rev Chg Q | 24.2% |
| QoQ Delta Rev Chg LTM | 1,488.9% |
| Op Mgn LTM | -30.7% |
| Op Mgn 3Y Avg | -154.2% |
| QoQ Delta Op Mgn LTM | 2,696.9% |
| CFO/Rev LTM | -13.5% |
| CFO/Rev 3Y Avg | -147.1% |
| FCF/Rev LTM | -24.6% |
| FCF/Rev 3Y Avg | -156.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.1 |
| P/S | 12.0 |
| P/EBIT | -0.9 |
| P/E | -1.0 |
| P/CFO | -1.0 |
| Total Yield | -8.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -10.7% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -2.4% |
| 3M Rtn | 6.9% |
| 6M Rtn | 27.6% |
| 12M Rtn | 31.6% |
| 3Y Rtn | 101.7% |
| 1M Excs Rtn | -3.7% |
| 3M Excs Rtn | 13.3% |
| 6M Excs Rtn | 9.5% |
| 12M Excs Rtn | 19.8% |
| 3Y Excs Rtn | 13.5% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Research, development and eventual commercialization of precision oncology drugs targeting specific | 132 | 8 | |||
| Total | 132 | 8 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Research, development and eventual commercialization of precision oncology drugs targeting specific | 254 | 357 | 103 | ||
| Total | 254 | 357 | 103 |
Price Behavior
Price Behavior
| Market Price | $2.65 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 06/19/2020 | |
| Distance from 52W High | 0.0% | |
| 50 Days | 200 Days | |
| DMA Price | $2.33 | $1.74 |
| DMA Trend | up | up |
| Distance from DMA | 13.8% | 52.0% |
| 3M | 1YR | |
| Volatility | 78.7% | 60.1% |
| Downside Capture | -104.10 | 17.70 |
| Upside Capture | 128.63 | 99.64 |
| Correlation (SPY) | -2.7% | 12.2% |
RPTX Betas & Captures as of 12/31/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.52 | -0.29 | -0.00 | 0.37 | 0.34 | 0.97 |
| Up Beta | -3.66 | 0.03 | -0.31 | -0.39 | -0.03 | 0.25 |
| Down Beta | 1.59 | -0.41 | 0.16 | -0.13 | 0.74 | 0.98 |
| Up Capture | 436% | 148% | 124% | 189% | 73% | 89% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 10 | 17 | 29 | 65 | 112 | 328 |
| Down Capture | 13% | -168% | -96% | 9% | 15% | 111% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 11 | 20 | 29 | 52 | 106 | 379 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RPTX | |
|---|---|---|---|---|
| RPTX | 121.0% | 60.4% | 1.53 | - |
| Sector ETF (XLV) | 9.2% | 17.3% | 0.35 | 18.7% |
| Equity (SPY) | 15.5% | 19.3% | 0.62 | 12.0% |
| Gold (GLD) | 87.8% | 20.6% | 2.98 | 4.3% |
| Commodities (DBC) | 10.6% | 15.5% | 0.45 | 6.9% |
| Real Estate (VNQ) | 3.6% | 16.5% | 0.04 | 20.7% |
| Bitcoin (BTCUSD) | -15.6% | 39.7% | -0.33 | 14.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RPTX | |
|---|---|---|---|---|
| RPTX | -41.7% | 75.6% | -0.36 | - |
| Sector ETF (XLV) | 7.2% | 14.5% | 0.32 | 22.1% |
| Equity (SPY) | 14.1% | 17.1% | 0.66 | 26.3% |
| Gold (GLD) | 22.3% | 15.7% | 1.14 | 6.3% |
| Commodities (DBC) | 12.3% | 18.7% | 0.53 | 4.2% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 24.1% |
| Bitcoin (BTCUSD) | 20.0% | 57.9% | 0.55 | 12.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RPTX | |
|---|---|---|---|---|
| RPTX | -21.7% | 75.0% | -0.24 | - |
| Sector ETF (XLV) | 10.6% | 16.6% | 0.53 | 22.0% |
| Equity (SPY) | 15.8% | 17.9% | 0.76 | 25.5% |
| Gold (GLD) | 16.5% | 14.9% | 0.92 | 6.9% |
| Commodities (DBC) | 8.9% | 17.6% | 0.42 | 4.1% |
| Real Estate (VNQ) | 5.9% | 20.8% | 0.25 | 22.9% |
| Bitcoin (BTCUSD) | 72.5% | 66.5% | 1.11 | 13.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/14/2025 | 32.1% | 27.9% | 32.7% |
| 8/8/2025 | 1.0% | 2.6% | 12.5% |
| 3/3/2025 | -1.7% | 0.4% | -16.4% |
| 11/7/2024 | -3.3% | -9.7% | -12.7% |
| 8/6/2024 | -8.0% | -8.4% | -14.9% |
| 2/28/2024 | -0.9% | -1.1% | -29.9% |
| 11/9/2023 | -10.8% | 28.7% | 54.5% |
| 8/9/2023 | 17.1% | 13.2% | 24.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 12 | 10 |
| # Negative | 9 | 7 | 9 |
| Median Positive | 3.0% | 6.6% | 20.5% |
| Median Negative | -1.7% | -8.4% | -12.7% |
| Max Positive | 32.1% | 28.7% | 54.5% |
| Max Negative | -10.8% | -14.3% | -29.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/03/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 03/01/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Koehler, Maria | EVP, CHIEF MEDICAL OFFICER | Direct | Sell | 3142025 | 1.14 | 3,596 | 4,099 | 259,707 | Form |
| 2 | Zinda, Michael | EVP, CHIEF SCIENTIFIC OFFICER | Direct | Sell | 3142025 | 1.14 | 5,611 | 6,397 | 91,539 | Form |
| 3 | Forte, Steve | EVP, CHIEF FINANCIAL OFFICER | Direct | Sell | 3142025 | 1.14 | 6,884 | 7,848 | 62,456 | Form |
| 4 | Segal, Lloyd Mitchell | PRESIDENT AND CEO | Direct | Sell | 3142025 | 1.14 | 21,179 | 24,144 | 141,809 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.